• Publications
  • Influence
Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer
TLDR
EBI significantly increased CNS metastasis-free interval with a beneficial effect that was significant in males, patients with weight loss less than 6%, squamous cell histology or responders, and patients with good performance status or no prior therapy. Expand
High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
TLDR
In conclusion, intensification with high-dose chemotherapy can increase the CR rate, and this approach is most likely to show long-term benefits in patients with minimal disease (CR) at the beginning of intensification therapy. Expand
Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.
TLDR
All the treatment arms have similar antitumor activity in non-small-cell lung cancer, but the PVP combination is slightly less toxic than the PVD and PVPVD treatment arms. Expand
Pharmacokinetic studies during phase I trials of high-dose thymidine infusions.
TLDR
Calculations and comparison to other studies at lower infusion rates indicate that thymidine is metabolized significantly by organs in addition to the liver and that, at millimolar plasma Thymidine, total body metabolic processes of thymazine are saturated as is the secretory portion of kidney clearance. Expand
Is there cumulative or delayed toxicity from Cis‐platinum?
TLDR
It was concluded that cumulative, delayed or severe nephrotoxicity are not significant problems related to prolonged cis‐platinum administration at moderate doses when hydration and diuretics are routinely used. Expand
Use of carcinoembryonic antigen in small cell lung cancer prognostic value and relation to the clinical course 1
TLDR
It is recommended that CEA be measured in this disease at diagnosis as an additional prognostic factor and that patients with abnormal initial CEA levels have follow‐up measurements to aid in evaluating response. Expand
Clinical trials with the hexitol derivatives in the U.S.
TLDR
DBD was disappointing in breast cancer and in several other malignancies, but some activity has been noted against lung cancer, and DAG is being investigated for possible usefulness in the management of patients with intracranial neoplasms. Expand
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
TLDR
It is demonstrated that VM-26 can produce tumor responses in refractory lymphomas and two patients with diffuse histiocytic lymphoma complete remissions were documented. Expand
Cutaneous and subcutaneous metastases of lung cancer. Clinical characteristics.
TLDR
This data indicates that metastatic lesions to the skin and subcutaneous lymph nodes are less common than metastases to other organs, but they provide a valuable clue to what may be an otherwise quiescent primary lesion. Expand
Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
TLDR
Phase II studies with m-AMSA, in hematological cancers are warranted, since its most consistent effect is on leukocytes. Expand
...
1
2
3
4
5
...